July 2025

Contents

Journal scan

• Call to drop abacavir from use in adults

In memory

• AIDS quilts at the Tate: reflection and also anger

Early access

• US government has altered more than 100 scientific databases since 20 January

Special reports

• Why the new HIV PrEP guidelines from the UK are so exciting (2025)

• UK HIV care for transgender and non-binary people: EHRC guidance is unworkable

Conference reports

• 13th IAS Conference on HIV Science (IAS 2025): Introduction and early reports

• Once-weekly oral ART with ulonivirine plus islatravir: 24-week phase 2 results

• IAS 2025: Reduced dosing could be a safe option for adults: crisis response to ART stock-outs

• IAS 2025: 5-on 2-off dosing is inferior to continuous ART in BREATHER Plus – but no difference in clinical outcomes

• IAS 2025: Long-acting CAB/RPV in people with suboptimal adherence: IMPALA study results at 48 weeks

• !AS 2025: Once-monthly oral PrEP using MK-8527: the drug that will stop HIV

• IAS 2025: “We will not be erased” – a community Call to Action

• IAS 2025: HIV care is political: early focus on the funding crisis

• IAS 2025: HIV cure research at IAS 2025

• IAS 2025: Kigali Call to Action: sign-on to global leaders

Antiretrovirals

• Phase 2/3 studies put on hold for two once-weekly Gilead compounds

• Long-acting injectable PrEP approved in the US: priced at $28,000 a year

Treatment access

• Signal that sliver of PEPFAR might be salvaged

• Global Fund plans for lenacapavir PrEP in selected countries

• Latest news on US crisis (3 July): legal challenges, Global Fund, WHO, Kigali conference

• Latest on US crisis (26 June): Global Fund, GAVI and RFK Jr

• Latest on US crisis (13 June): legal and organisational responses

• HIV organisations support trans and non-binary communities against the unworkable EHRC guidance

Guidelines

• UK PrEP 2025 guidelines online

Future meetings

• Future meetings and webinars 2025